EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial

Zhuoran Yang, Yuxin Xu, Hu Du, Wenya Liu, Haiyan Chen, Dongfang Liu, Lili Zhang iD, Cong Wang iD

Diabetes, Obesity and Metabolism · 2026-08 · 28 (8) · 7380-7392

DOI: 10.1111/dom.70966 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.06.2026. Verfasst von Zhuoran Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Metformin, Obesity, Overweight. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau), Chongqing Municipal Health Commission, Natural Science Foundation Project of Chongqing CSTC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to assess the effects of low‐dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). Materials and Methods Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks. The primary outcome was the change in body weight. Secondary outcomes included changes in anthropometric measures other than body weight, body composition, reproductive hormone levels, metabolic and endocrine parameters, inflammatory markers and menstrual cycle regularity. All outcomes were assessed at baseline and week 16. After week 16, participants were switched to MET monotherapy. Barrier contraception was required for 8 weeks and pregnancy outcomes were subsequently evaluated between weeks 25 and 48.

Results

After 16 weeks of treatment, compared with the MET group, the COM group resulted in greater reductions in weight (−1.7 ± 2.5 kg vs. −10.4 ± 3.5 kg; p < 0.001), body mass index (BMI) (−0.68 ± 1.82 vs. −4.12 ± 1.37 kg/m 2 ; p < 0.001), visceral adipose tissue (VAT) (−4.67 ± 9.59 vs. −34.13 ± 15.33 cm 2 ; p < 0.001) and reproductive endocrine‐metabolic parameters. Menstrual cycle recovery and total pregnancy rate were higher in the COM group than in the MET group ( p = 0.013 and p = 0.014, respectively).

Conclusions

In overweight/obese women with PCOS, low‐dose tirzepatide combined with MET was associated with greater reductions in body weight and visceral fat, along with improvements in metabolic and reproductive outcomes compared with MET monotherapy. Trial Registration: ChiCTR2400090908; chictr.org.cn .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsMetforminObesityOverweightPolycystic Ovary SyndromeAdultFemaleHumansPregnancyYoung AdultBody Mass IndexChinaDrug Therapy, CombinationProspective StudiesTirzepatideTreatment OutcomeWeight Loss

Stichwörter der Autor:innen

body compositionmetforminpolycystic ovary syndromepregnancytirzepatide

Substanzen

Hypoglycemic AgentsMetforminTirzepatide

Autor:innen und Institutionen

  • Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Lili Zhang, Cong Wang

Förderung

  • Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau)
  • Chongqing Municipal Health Commission
  • Natural Science Foundation Project of Chongqing CSTC

Zitieren

APA

Yang, Z., Xu, Y., Du, H., Liu, W., Chen, H., Liu, D., Zhang, L., & Wang, C. (2026). Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial. Diabetes, Obesity and Metabolism, 28(8), 7380-7392. https://doi.org/10.1111/dom.70966

Vancouver

Yang Z, Xu Y, Du H, Liu W, Chen H, Liu D, et al. Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial. Diabetes, Obesity and Metabolism. 2026;28(8):7380-7392. doi:10.1111/dom.70966

BibTeX
@article{Yang2026,
  author = {Yang, Zhuoran and Xu, Yuxin and Du, Hu and Liu, Wenya and Chen, Haiyan and Liu, Dongfang and Zhang, Lili and Wang, Cong},
  title = {Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {8},
  pages = {7380--7392},
  doi = {10.1111/dom.70966}
}
Kostenlos starten →